12957_2020_1792_MOESM4_ESM.tif (5.19 MB)
MOESM4 of Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
figure
posted on 2020-01-21, 05:11 authored by Jiahang Mo, Xiao Hu, Lihu Gu, Bangsheng Chen, Parikshit Khadaroo, Zefeng Shen, Lei Dong, Yuqi Lv, Marylin Chitumba, Jiequan LiuAdditional file 4: Figure S4. Forest plot of the long-term prognostic outcomes of anti-PD-1/PD-L1 monotherapy in other cancer (Non-smoker vs. Smoker), PNon-smoker=0.094, PSmoker=0.001.
